|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB | |
Other (Supplementary Material)
21MB |
Item Type: | Article |
---|---|
Title: | Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis |
Creators Name: | Campa, C.C. and Silva, R.L. and Margaria, J.P. and Pirali, T. and Mattos, M.S. and Kraemer, L.R. and Reis, D.C. and Grosa, G. and Copperi, F. and Dalmarco, E.M. and Lima-Júnior, R.C.P. and Aprile, S. and Sala, V. and Dal Bello, F. and Prado, D.S. and Alves-Filho, J.C. and Medana, C. and Cassali, G.D. and Tron, G.C. and Teixeira, M.M. and Ciraolo, E. and Russo, R.C. and Hirsch, E. |
Abstract: | PI3K activation plays a central role in the development of pulmonary inflammation and tissue remodeling. PI3K inhibitors may thus offer an improved therapeutic opportunity to treat non-resolving lung inflammation but their action is limited by unwanted on-target systemic toxicity. Here we present CL27c, a prodrug pan-PI3K inhibitor designed for local therapy, and investigate whether inhaled CL27c is effective in asthma and pulmonary fibrosis. Mice inhaling CL27c show reduced insulin-evoked Akt phosphorylation in lungs, but no change in other tissues and no increase in blood glycaemia, in line with a local action. In murine models of acute or glucocorticoid-resistant neutrophilic asthma, inhaled CL27c reduces inflammation and improves lung function. Finally, inhaled CL27c administered in a therapeutic setting protects from bleomycin-induced lung fibrosis, ultimately leading to significantly improved survival. Therefore, local delivery of a pan-PI3K inhibitor prodrug reduces systemic on-target side effects but effectively treats asthma and irreversible pulmonary fibrosis. |
Keywords: | Animal Disease Models, Asthma, Bleomycin, Enzyme Inhibitors, Inbred BALB C Mice, Inbred C57BL Mice, Inhalation Administration, Ovalbumin, Phosphatidylinositol 3-Kinases, Phosphorylation, Proto-Oncogene Proteins c-akt, Pulmonary Fibrosis, Animals, Mice |
Source: | Nature Communications |
ISSN: | 2041-1723 |
Publisher: | Nature Publishing Group |
Volume: | 9 |
Number: | 1 |
Page Range: | 5232 |
Date: | 12 December 2018 |
Official Publication: | https://doi.org/10.1038/s41467-018-07698-6 |
PubMed: | View item in PubMed |
Repository Staff Only: item control page